Cardiovascular-kidney-metabolic (CKM) syndrome is characterized by complex pathophysiological interactions between metabolic risk factors, chronic kidney disease (CKD) and cardiovascular system, leading to a high rate of cardiovascular events. The main etiology of CKM syndrome is related to obesity (excess or dysfunctional fatty tissue or both). Obese patients have dysfunctional visceral adipose tissue, that secretes proinflammatory and pro-oxidative molecules, with adverse effects on arterial, cardiac and kidney tissues¹. Chronic inflammation further decreases insulin sensitivity, leading to an impaired glucose tolerance¹. The appearance of metabolic dysfunction-associated steatotic liver disease (MASLD) increases systemic inflammation and insulin resistance². MASLD is currently the main cause of liver failure and liver transplantation³. The proinflammatory and pro-oxidative mediators enhance the pathophysiological mechanisms responsible for atherosclerosis and myocardial injury, but also for kidney inflammation and fibrosis, through endothelial damage and sheer stress. CKD is a very important amplifier of cardiovascular risk, through albuminuria and low glomerular filtration rate (GFR). The most common causes of mortality in diabetes patients with CKD are atherosclerotic cardiovascular disease and heart failure⁴; only a minority of patients with CKD will survive to progress to kidney failure⁵.
Recently (June 9, 2026), a new report on the prevention, detection, evaluation and management of CKM syndrome was published by the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines⁶, to offer current knowledge in the field of CKM syndrome. The most important recommendations of this new guideline on CKM syndrome are⁶:
- Staging of CKM syndrome must be done in all affected patients, to individualize therapy and reduce the risk of cardiovascular events and kidney function loss.
- In patients at risk for cardiovascular disease, the risk must be assessed using the PREVENT (Predicting Risk of Cardiovascular Disease EVENTS) equation, that estimate the 10- and 30-year risk for atherosclerotic cardiovascular disease and heart failure.
- Routine evaluations for metabolic risk factors and kidney function are recommended in all adults.
- To implement a patient-centered strategy, the use of interdisciplinary care models is needed for patients with overlap among the CKM syndrome conditions, such as type 2 diabetes, CKD and cardiovascular diseases.
- Overweight and obesity must be assessed using body mass index and waist circumference. In overweight or obese patients, lifestyle changes are needed, with additional use of drug treatment for obesity or bariatric surgery.
- In patients with type 2 diabetes, at risk for cardiovascular disease or already diagnosed with cardiovascular disease, antihyperglycemic drugs with cardioprotective effects are recommended, such as sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 (GLP-1)–based therapy. The selection of pharmacological treatment must be guided by comorbidities.
- Estimated GFR and urine albumin-to-creatinine ratio (UACR) are used to assess the severity of CKD and select the nephroprotective treatment with cardiovascular benefits. In diabetes patients with CKD, renin-angiotensin system inhibitors and SGLT2i should be used as first-line treatment.
- The CKM syndrome must be integrated into heart failure management. In patients with heart failure with reduced ejection fraction, angiotensin receptor-neprilysin inhibitors (ARNI), angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB) and SGLT2i have cardiovascular and kidney benefits. In patients with heart failure with mildly reduced ejection fraction/ heart failure with preserved ejection fraction, SGLT2i are the first-line treatment, and GLP-1–based drugs are needed in patients with obesity or other CKM risk factors. Nonsteroidal mineralocorticoid receptor antagonists are used to reduce adverse cardiovascular events and loss of kidney function in patients with type 2 diabeets and CKD.
Address for correspondence:
Camelia C. DIACONU
E-mail: drcameliadiaconu@gmail.com